Jump to content



Recommended Posts

Couple of items:


1. Not sure whether its been posted before or not; however, the FDA Meeting: "Patient-Focussed drug Development for Vitiligo" programmed for yesterday to allow the FDA to obtain patient perspectives on the impact of Vitiligo on daily life, was postponed until further notice.


2. SHORT SELLING - Petition: There is provision advertised on the following shortman link - https://www.shortman.com.au/stock?q=CUV - for persons interested to sign a petition to Government supporting the banning the short selling of shares on the ASX. I get the impression Billy Boots might be interested in supporting this campaign! Anyone else ??


Link to comment
Share on other sites

  • Replies 51.4k
  • Created
  • Last Reply

Top Posters In This Topic

  • royco


  • Kiwi1


  • seeva222


  • Reality Check


Top Posters In This Topic

Posted Images

Could someone in the know please explain the shorter's game with CUV?. One would think they would have collected when the SP was down at $13. On the contrary, the % is growing. With US sales just around the corner, I don't get it??? So far they haven't put a foot wrong so half expecting another tumble in the SP.
Link to comment
Share on other sites

Reuters Health Information: Better Outcomes of Erythropoietic Protoporphyria Seen With Afamelanotide Use, by Will Boggs MD (March 30, 2020)


Some highlights:


  • "Offer this to your patients when financially possible; it is a life changer," Dr. Janneke G. Langendonk of Erasmus MC, University Medical Center, in Rotterdam, told Reuters Health by email.
  • Dr. Langendonk and colleagues investigated the outcomes of afamelanotide treatment in their single-center, single-arm prospective postauthorization safety and efficacy study of 117 patients with EPP.
  • Patients received a controlled-release 16-mg subcutaneous implant of afamelanotide with an interval of at least 60 days and a maximum of four implants per year. In week 1, time spent outside rose a mean 1.85 hours per week with afamelanotide (P=0.06). By week 5, time spent outside had increased an average of 6.14 hours per week (P<0.001).
  • The most common adverse events were nausea, fatigue/malaise, flushing and nausea with headache, all of which were self-limiting with a mean duration of one to two days directly after implantation. There were no treatment-related serious adverse events.
  • Dr. Manisha Balwani of Icahn School of Medicine at Mount Sinai, in New York City, who studies porphyria but was not involved in the new work, told Reuters Health by email, "The most interesting finding is that patients responded to the drug regardless of baseline disease severity and that the effects improved over years of treatment." "Afamelanotide does not address the elevated protoporphyrin level or the ferrochelatase-enzyme deficiency," she explained. "It does not have any impact on liver disease in EPP."
Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...